Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer-Reference-Cited by-同舟云学术

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

Published:2017-10 Issue: Volume:112 Page:181-187
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Reck Martin,Paz-Ares Luis,Bidoli Paolo,Cappuzzo Federico,Dakhil Shaker,Moro-Sibilot Denis,Borghaei Hossein,Johnson Melissa,Jotte Robert,Pennell Nathan A.,Shepherd Frances A.,Tsao Anne,Thomas Michael,Carter Gebra Cuyun,Chan-Diehl Faye,Alexandris Ekaterine,Lee Pablo,Zimmermann Annamaria,Sashegyi Andreas,Pérol Maurice

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Cancer statistics, 2016;Siegel;CA. Cancer J. Clin.,2016

2. Targeting angiogenesis in non-small cell lung cancer: Agents in practice and clinical development;Barzi;Eur. J. Clin. Med. Oncol.,2010

3. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann. Oncol.,2014

4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N. Engl. J. Med.,2006

5. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer;Scagliotti;J. Clin. Oncol.,2010

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne;Revue des Maladies Respiratoires Actualités;2023-10

2. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives;Lung Cancer;2023-05

3. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2023-04

4. Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting;Anticancer Research;2023-02-28

5. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study;European Journal of Clinical Pharmacology;2023-02-11